PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

GSK ‘Well Positioned’ for Potential Tariffs After Beating Forecasts

GSK reaffirmed its 2025 outlook and said it was “well positioned” to absorb potential U.S. pharmaceutical tariffs, after reporting stronger-than-expected first-quarter results.

The British drugmaker’s shares rose 2.4% to about 14.7 pounds by 0750 GMT, among the top gainers on London’s FTSE 100 index, which was up 0.06%.

U.S. President Donald Trump has proposed sector-specific tariffs, including an as-yet unspecified “major” levy on pharmaceuticals, prompting concern given the pharma industry’s interwoven global supply chain.

Advertisement · Scroll to continue

One report estimated pharma tariffs could raise U.S. drug costs by $51 billion annually.

GSK said it had identified options within its supply chain and productivity initiatives to mitigate any hit from pharmaceutical tariffs, but did not provide details.

GSK CEO Emma Walmsley has been focusing on expanding newer products, including within the company’s infectious diseases portfolio, to offset declining sales from its top-selling drugs and vaccines as demand slows and competition increases.

GSK is also preparing for looming patent expirations in its HIV portfolio.

“(The momentum in the company’s portfolio), together with the strength of our portfolio and proven ability to drive operating leverage, underpin our confidence in guidance for the year and our longer-term outlooks,” Walmsley said.

GSK reported first-quarter turnover of 7.52 billion pounds ($10.07 billion) and core profit of 44.9 pence per share, narrowly ahead of analysts’ average expectation of 7.42 billion pounds and 40.9 pence per share, respectively, according to a company-compiled consensus, opens new tab.

In the same period last year, GSK reported turnover of 7.36 billion pounds and core profit of 43.1 pence per share.

However, sales at its vaccine unit were down 6% to 2.1 billion pounds, with its newer RSV vaccine Arexvy bringing in just 0.1 billion pounds, down 57%.

GSK initially had projected Arexvy to be a blockbuster product, estimating peak annual sales of 3 billion pounds, but sales have missed market expectations for the past several quarters.

In February, GSK lifted its long-term sales target to over 40 billion pounds by 2031, but uncertainties around pharmaceutical import tariffs and the Trump administration’s policies on vaccines and HIV prevention loom large on drugmakers in the near term.00:04A new sperm racing event highlights male fertility decline

For 2025, the company continues to expect turnover to grow 3-5% and core earnings per share to rise 6-8% at constant currency rates.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026